BostonGene and Massachusetts General Hospital to Collaborate on Multiple Follicular Lymphoma Research Projects

BostonGene与马萨诸塞州总医院合作开展多滤泡淋巴瘤研究项目

2021-10-13 00:00:10 BioSpace

本文共1277个字,阅读需4分钟

An indolent B-cell lymphoma, FL can transform into an aggressive lymphoma; however, the underlying causes of transformation remain unknown. To elucidate the molecular mechanisms and the role of the microenvironment in this process, Abner Louissaint MD, PhD, of the Department of Pathology at the MGH, developed a unique PDX mouse model of FL transformation. In support of this work, BostonGene performs large-scale analytics utilizing next generation sequencing and multiplex immunofluorescence imaging to provide insight into the cellular composition and spatial architecture of the reconstructed patient tumor and microenvironment in these PDX mouse models. BostonGene computational modeling of the molecular profiles of the primary patient FL tumors and the PDX tumors uncovers which patients may undergo transformation. This collaborative project drives the utilization of FL PDX mouse models in the personalization of therapy, the discovery of potential therapies for transformed FL, and the identification of biomarkers of transformation. A second study focuses on the elucidation of the role of tumor microenvironment on FL patients’ response to treatments. Jacob Soumerai, MD, a clinical lymphoma investigator at the MGH Cancer Center, in collaboration with Dr. Louissaint are evaluating the influence of tumor genetics and tumor microenvironment composition on FL patient response and the development of resistance to the combinatorial therapy of rituximab and umbralisib, a PI3Kδ inhibitor. As part of this study, BostonGene provides integrated transcriptomic and genomic analysis of FL patients treated with this combination therapy such as the identification of somatic alterations, evaluation of gene expression, estimation of tumor heterogeneity, microenvironment classification and neoantigen prediction. This work will determine biomarkers of FL patient response to PI3Kδ inhibition, ultimately improving the clinical outcomes of this patient population. “By using an analytical approach to further understand the cellular composition of patients with follicular lymphoma and identify biomarker response to therapy, we are hopeful that we can be better informed when making individual treatment decisions,” said Dr. Louissaint, who is also an assistant professor of Pathology at Harvard Medical School. “We’re proud to collaborate with MGH by providing next-generation multi-platform analytics to evaluate the molecular and immunologic profiles of follicular lymphoma patients,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our analysis will define genomic and transcriptional alterations that serve as predictive biomarkers of response and resistance to therapy, enabling doctors to personalize treatment plans.” About BostonGene Corporation BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005704/en/ Media: BostonGene Erin O’Reilly +1-781-366-7049 Erin.Oreilly@BostonGene.com Source: BostonGene Corporation View this news release online at: http://www.businesswire.com/news/home/20211012005704/en
慢性B细胞淋巴瘤可转化为侵袭性淋巴瘤;然而,转变的根本原因仍然未知。为了阐明分子机制和微环境在这一过程中的作用,MGH病理学部的Abner Louissaint博士开发了一种独特的FL转化的PDX小鼠模型。为了支持这项工作,BostonGene利用下一代测序和多重免疫荧光成像进行大规模分析,以提供对这些PDX小鼠模型中重建患者肿瘤和微环境的细胞组成和空间结构的洞察力。BostonGene计算模拟了原发性患者FL肿瘤和PDX肿瘤的分子图谱,揭示了哪些患者可能发生转化。该合作项目推动了FL PDX小鼠模型在治疗个性化、发现转化FL的潜在疗法以及识别转化的生物标志物方面的应用。 第二项研究侧重于阐明肿瘤微环境对FL患者治疗反应的作用。MGH癌症中心的临床淋巴瘤研究员Jacob Soumerai医学博士与Louissaint博士合作,正在评估肿瘤遗传学和肿瘤微环境组成对FL患者反应的影响,以及对利妥昔单抗和Imbralisib(一种PI3Kδ抑制剂)组合治疗的耐药性发展。作为这项研究的一部分,BostonGene为接受这种联合治疗的FL患者提供了完整的转录组和基因组分析,如识别体细胞改变、评估基因表达、估计肿瘤异质性、微环境分类和新抗原预测。这项工作将确定FL患者对PI3Kδ抑制反应的生物标志物,最终改善该患者群体的临床结果。 “通过使用分析方法进一步了解滤泡性淋巴瘤患者的细胞组成,并确定对治疗的生物标志物反应,我们希望在做出个人治疗决定时能够更好地了解情况,”路易斯森博士说,他也是哈佛医学院的病理学助理教授。 波士顿基因公司首席医疗官、医学博士内森·福勒(Nathan Fowler)说:“我们很自豪能与MGH合作,提供下一代多平台分析来评估滤泡淋巴瘤患者的分子和免疫学特征。”“我们的分析将定义基因组和转录变化,作为治疗反应和耐药性的预测性生物标志物,使医生能够个性化治疗计划。” 关于BostonGene公司 BostonGene的使命是通过基于AI的分子和免疫分析来推动医疗保健向个性化医疗的过渡,以提高护理标准,加快研究,并改善经济学。BostonGene肿瘤肖像试验揭示了每个肿瘤的关键驱动因素,包括免疫微环境特性、可操作突变、对不同疗法反应的生物标志物和推荐的疗法。通过这些综合分析,BostonGene肿瘤肖像TM测试为每个癌症患者的治疗决策生成个性化路线图。欲了解更多信息,请访问BostonGene:http://www.BostonGene.com。 在businesswire.com查看源代码版本:https://www.businesswire.com/news/home/20211012005704/en/ 媒体: 波士顿吉恩 艾琳·奥赖利 +1-781-366-7049 @bostongene.com 资料来源:BostonGene Corporation 在网上查看此新闻稿: http://www.businesswire.com/news/home/20211012005704/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文